These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22788122)

  • 1. Vaccine adjuvants: is the pipeline clogged?
    Leitner WW
    Immunotherapy; 2012 Jun; 4(6):565-7. PubMed ID: 22788122
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine adjuvants: current challenges and future approaches.
    Wilson-Welder JH; Torres MP; Kipper MJ; Mallapragada SK; Wannemuehler MJ; Narasimhan B
    J Pharm Sci; 2009 Apr; 98(4):1278-316. PubMed ID: 18704954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.
    Klinman DM; Klaschik S; Sato T; Tross D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):248-55. PubMed ID: 19272313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New adjuvants for human vaccines.
    Mbow ML; De Gregorio E; Valiante NM; Rappuoli R
    Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
    Bracci L; La Sorsa V; Belardelli F; Proietti E
    Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond empiricism: informing vaccine development through innate immunity research.
    Levitz SM; Golenbock DT
    Cell; 2012 Mar; 148(6):1284-92. PubMed ID: 22424235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technologies for enhanced efficacy of DNA vaccines.
    Saade F; Petrovsky N
    Expert Rev Vaccines; 2012 Feb; 11(2):189-209. PubMed ID: 22309668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter from the editor.
    Ellis R; Riedmann EM
    Hum Vaccin Immunother; 2014; 10(4):813-4. PubMed ID: 24784356
    [No Abstract]   [Full Text] [Related]  

  • 10. The impact of vaccines and vaccinations: Challenges and opportunities for modelers.
    Curtiss R
    Math Biosci Eng; 2011 Jan; 8(1):77-93. PubMed ID: 21361401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 'perfect' adjuvant, a stronger voice.
    Glenn GM
    Expert Rev Vaccines; 2011 Apr; 10(4):399-400. PubMed ID: 21506634
    [No Abstract]   [Full Text] [Related]  

  • 12. Multivalent minigene vaccines against infectious disease.
    An LL; Whitton JL
    Curr Opin Mol Ther; 1999 Feb; 1(1):16-21. PubMed ID: 11249678
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mucosal vaccine: the powerful weapon for the host defense].
    Takahashi I
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():632-6. PubMed ID: 17455694
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvants for cancer vaccines.
    Dubensky TW; Reed SG
    Semin Immunol; 2010 Jun; 22(3):155-61. PubMed ID: 20488726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock proteins as vaccine adjuvants in infections and cancer.
    Segal BH; Wang XY; Dennis CG; Youn R; Repasky EA; Manjili MH; Subjeck JR
    Drug Discov Today; 2006 Jun; 11(11-12):534-40. PubMed ID: 16713905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy: friend or foe to cancer vaccines?
    Emens LA; Machiels JP; Reilly RT; Jaffee EM
    Curr Opin Mol Ther; 2001 Feb; 3(1):77-84. PubMed ID: 11249735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX-1401 combined with TLR agonist: positive phase 1 results.
    Riedmann EM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1742. PubMed ID: 23980263
    [No Abstract]   [Full Text] [Related]  

  • 18. Innate immunity and new adjuvants.
    Mutwiri G; Gerdts V; Lopez M; Babiuk LA
    Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine adjuvants.
    Glenn G
    Expert Rev Vaccines; 2003 Apr; 2(2):163-4. PubMed ID: 12899568
    [No Abstract]   [Full Text] [Related]  

  • 20. TLR4 agonists as vaccine adjuvants: a chemist's perspective.
    Johnson DA
    Expert Rev Vaccines; 2013 Jul; 12(7):711-3. PubMed ID: 23885814
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.